CHP
PCRX icon

Cable Hill Partners’s Pacira BioSciences PCRX Stock Holding History

Cable Hill Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-22
Closed -$1K – 877
2016
Q3 		$1K Buy
+22
New +$862 ﹤0.01% 833

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cable Hill Partners's PCRX Position: Q4 2016 in Review

Cable Hill Partners sold out of Pacira BioSciences (PCRX) in Q4 2016, closing a stake of 22 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in PCRX in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • Cable Hill Partners reported no remaining Pacira BioSciences position as of Q4 2016 after selling out during the quarter.
  • Cable Hill Partners sold 22 Pacira BioSciences shares in Q4 2016, an estimated $1K.
  • Cable Hill Partners first reported a position in Pacira BioSciences in Q3 2016 and held it in 1 quarter.
  • Cable Hill Partners's Pacira BioSciences position peaked at $1K in Q3 2016.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on Cable Hill Partners's 13F filing for Q4 2016, filed 10 Feb 2017.